Clinical and morphologic predictors of outcome in older aplastic anemia patients treated with eltrombopag

Treatment of aplastic anemia (AA) in the elderly is particularly challenging due to higher toxicity and lower efficacy of the available therapies. In fact, 30-40% of patients eligible for intensive immunosuppressive treatment (IST) with horse antithymocyte globulin (ATG) plus cyclosporine (CyA) will